Checkpoint inhibitors act on either the PD1/PD-L1 axis or CTLA-4 on T cells which reduces the interaction between cancer cells and immune effector cells, preventing the tumor cells from immune escape [65]. The gene discussed is CD274; the disease is neoplasm.